Advertisement
Advertisement
U.S. Markets open in 9 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Decibel Therapeutics, Inc. (DBTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.2400-0.2500 (-10.04%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4900
Open2.4200
Bid2.2400 x 900
Ask2.9600 x 900
Day's Range2.2300 - 2.4700
52 Week Range1.8310 - 9.7500
Volume56,086
Avg. Volume72,267
Market Cap55.828M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference

    BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET. A live webcast of the fireside chat

  • GlobeNewswire

    Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T

  • GlobeNewswire

    Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

    - Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program – - New preclinical data presented at the 45th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective transgene expression – - Preclinical data to be presented at the Americ

Advertisement
Advertisement